Activation of the plasma clotting, fibrinolytic, and kinin-kallikrein system in preterm infants with severe idiopathic respiratory distress syndrome.
We studied the activation pattern of clotting, fibrinolysis, and kinin-kallikrein during the first 5 d of life in 10 preterm infants with signs of severe idiopathic respiratory distress syndrome (IRDS) after birth (IRDS group) and in 12 healthy preterm infants (reference group). We found systemic activation of clotting, fibrinolysis, and kinin-kallikrein in the IRDS infants within 12 to 24 h of birth, represented by increased median thrombin-antithrombin III complex formation (90 ng/mL versus 10 ng/mL in the reference group, p < 0.05), increased mean tissue-type plasminogen activator plasma concentrations (11.8 ng/mL versus 3.5 ng/mL in the reference group, p < 0.05), and increased mean plasma kallikrein activity (182.6% versus 162.0% of maximal activated human plasma in the reference group, p < 0.05), respectively. Clotting activation was accompanied by a significant decrease of the platelet count. Clotting and fibrinolytic activity decreased in the IRDS group during the first 2 to 3 d of life. Kinin-kallikrein activation was accompanied by decreased plasma kallikrein inhibitor activity values and did not change throughout the study period. Plasma factor XII activity was not significantly increased in the IRDS infants during the first 2 d of life but did significantly increase thereafter. The cause of simultaneous activation of clotting, fibrinolysis, and kinin-kallikrein in our IRDS infants has not yet been clarified. However, this activation process may contribute to lung injury such as that described in the adult respiratory distress syndrome.
Brus
F
F
Beatrix Childrens Hospital, Division of Neonatology, University Hospital Groningen, The Netherlands.
van Oeveren
W
W
Okken
A
A
Oetomo
S B
SB
D000990:Antithrombin III / Q000378:metabolism; D001778:Blood Coagulation Disorders / Q000150:complications*; D001798:Blood Proteins / Q000378:metabolism; D015956:Factor XIIa / Q000378:metabolism; D005342:Fibrinolysis / Q000502:physiology*; D006801:Humans; D007231:Infant, Newborn; D007610:Kallikreins / Q000502:physiology*; D007705:Kinins / Q000502:physiology*; D010447:Peptide Hydrolases / Q000378:metabolism; D010976:Platelet Count; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000209:etiology / Q000503:physiopathology*; D010959:Tissue Plasminogen Activator / Q000378:metabolism
D001798:Blood Proteins; D007705:Kinins; C046193:antithrombin III-protease complex; D000990:Antithrombin III; D010447:Peptide Hydrolases; D007610:Kallikreins; D015956:Factor XIIa; D010959:Tissue Plasminogen Activator